Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Long-term depression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    198 result(s) found for: Long-term depression. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000512-82 Sponsor Protocol Number: OLA-D Start Date*: 2007-06-12
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design
    Medical condition: Major Depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003745-14 Sponsor Protocol Number: D1448C00005 Start Date*: 2006-01-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-centre, Double-blind, Randomised Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Monothe...
    Medical condition: Maintenance treatment of patients with Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001829-33 Sponsor Protocol Number: F1J-US-HMFA Start Date*: 2008-09-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression
    Medical condition: Major Depressive Disorder in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012378 Depression LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002097-38 Sponsor Protocol Number: ABR62020 Start Date*: 2018-06-05
    Sponsor Name:University Medical Centre Utrecht
    Full Title: SAMe as an epigenetic treatment of depression in people with childhood trauma, a double blind placebo-controlled trial
    Medical condition: Depressive episode in people with childhood trauma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001380-76 Sponsor Protocol Number: 14570A Start Date*: 2013-03-28
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole a...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    18.0 100000004873 10025463 Major depressive disorder, single episode LLT
    18.0 100000004873 10025469 Major depressive disorder, single episode, severe degree, without mention of psychotic behavior LLT
    18.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    18.0 100000004873 10025467 Major depressive disorder, single episode, moderate degree LLT
    18.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    18.0 100000004873 10025470 Major depressive disorder, single episode, unspecified degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) SE (Completed) FI (Completed) LT (Completed) GB (Completed) BG (Completed) IT (Prematurely Ended) LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024371-12 Sponsor Protocol Number: CN162-010 Start Date*: 2011-11-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A multicenter, Double-blind 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression.
    Medical condition: Subjects with Treatment Resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) SE (Completed) FI (Prematurely Ended) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002658-11 Sponsor Protocol Number: 12712B Start Date*: 2016-06-08
    Sponsor Name:H. Lundbeck A/S
    Full Title: Long-term, open-label, flexible-dose, continuation extension study with vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 17 years of age
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) LV (Completed) HU (Completed) EE (Completed) ES (Completed) IT (Completed) DE (Completed) BG (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001855-39 Sponsor Protocol Number: 001 Start Date*: 2005-09-05
    Sponsor Name:Psychiatric Research Unit, Frederiksborg General Hospital
    Full Title: Chronos: Can the antidepressive response induced by sleep deprivation (wake-therapy) be sustained through continuous stabilisation of the diurnal rhythm and long term light treatment in patients wi...
    Medical condition: Major depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003039-31 Sponsor Protocol Number: D1002002 Start Date*: 2015-08-20
    Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd.
    Full Title: A Long-Term Study of SM-13496 in Patients with Bipolar I Disorder
    Medical condition: Bipolar I depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003547-35 Sponsor Protocol Number: 16160A Start Date*: 2015-04-07
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, flexible-dose, long-term study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with a...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    18.0 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011911-19 Sponsor Protocol Number: QUE/09 Start Date*: Information not available in EudraCT
    Sponsor Name:Ludwig-Maximilian-University of Munich, Department of Psychiatry
    Full Title: Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients
    Medical condition: In this study, patients suffering from unipolar depression are investigated. 40 unipolar depressed inpatients (age 18-65) enter the study after the procedure has been fully explained and written in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012378 Depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007483-42 Sponsor Protocol Number: D1050256 Start Date*: 2009-10-21
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
    Medical condition: Bipolar I depression
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Completed) SK (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004169-42 Sponsor Protocol Number: 14767B Start Date*: 2013-08-14
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    16.0 100000004873 10025463 Major depressive disorder, single episode LLT
    16.0 100000004873 10025469 Major depressive disorder, single episode, severe degree, without mention of psychotic behavior LLT
    16.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    16.0 100000004873 10025467 Major depressive disorder, single episode, moderate degree LLT
    16.0 100000004873 10025457 Major depressive disorder, recurrent episode, mild degree LLT
    16.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    16.0 100000004873 10025470 Major depressive disorder, single episode, unspecified degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004291-18 Sponsor Protocol Number: 54135419TRD4010 Start Date*: 2021-04-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
    Medical condition: Treatment-Resistant Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) FI (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002108-11 Sponsor Protocol Number: SEP380-303 Start Date*: 2022-02-10
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ...
    Medical condition: Major Depressive Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001997-70 Sponsor Protocol Number: EXCELLENCE/0421/0543v1 Start Date*: 2022-11-16
    Sponsor Name:University of Cyprus
    Full Title: Efficacy of Ketamine for the Prevention of Relapse in Patients with Opioid-Use Disorders (OUD)
    Medical condition: Methadone and buprenorphine comprise a first-line, evidence-based opioid substitution treatment (OST) for OUD patients. Unfortunately, retention and adherence to OST treatment is currently a major ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10019935 Heroin addiction LLT
    20.1 10037175 - Psychiatric disorders 10030900 Opium addiction LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CY (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000905-31 Sponsor Protocol Number: 11492C Start Date*: 2007-05-03
    Sponsor Name:H. Lundbeck A/S
    Full Title: A long term open label, flexiable dose, extension study evaluationg the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder
    Medical condition: Indication: Major Depressive Disorder according to the DSM-IV-TR
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009710 CNS depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SE (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000430-42 Sponsor Protocol Number: 67953964MDD3003_VENTURA-LT Start Date*: 2023-06-22
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003252-20 Sponsor Protocol Number: ACP-103-055 Start Date*: 2019-06-11
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005356-25 Sponsor Protocol Number: 12712A Start Date*: 2016-07-27
    Sponsor Name:H. Lundbeck A/S
    Full Title: Long-term, open-label, flexible-dose, extension study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 18 years of age
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) HU (Completed) PL (Completed) IT (Prematurely Ended) ES (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 16:19:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA